Sugammadex: the first selective binding reversal agent for neuromuscular block☆☆☆
To access this article, please choose from the options below
☆ There were no sources of funding for the preparation of this manuscript.
☆☆ Dr. Kovac has received grant support from Organon (now Schering-Plough) and participated on the Speakers Bureau for Organon.
PII: S0952-8180(09)00218-9
doi:10.1016/j.jclinane.2009.05.002
© 2009 Elsevier Inc. All rights reserved.
